These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines. Galmarini CM; Warren G; Kohli E; Zeman A; Mitin A; Vinogradov SV Mol Cancer Ther; 2008 Oct; 7(10):3373-80. PubMed ID: 18852140 [TBL] [Abstract][Full Text] [Related]
5. N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer. Chen G; Svirskis D; Lu W; Ying M; Huang Y; Wen J J Control Release; 2018 May; 277():142-153. PubMed ID: 29548985 [TBL] [Abstract][Full Text] [Related]
6. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Bergman AM; Adema AD; Balzarini J; Bruheim S; Fichtner I; Noordhuis P; Fodstad O; Myhren F; Sandvold ML; Hendriks HR; Peters GJ Invest New Drugs; 2011 Jun; 29(3):456-66. PubMed ID: 20066470 [TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Wei X; Senanayake TH; Warren G; Vinogradov SV Bioconjug Chem; 2013 Apr; 24(4):658-68. PubMed ID: 23547842 [TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and γ-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma. Sun L; Zhou DS; Zhang P; Li QH; Liu P Int J Pharm; 2015 Jan; 478(1):308-317. PubMed ID: 25433201 [TBL] [Abstract][Full Text] [Related]
9. Comparison of nanogel drug carriers and their formulations with nucleoside 5'-triphosphates. Vinogradov SV; Kohli E; Zeman AD Pharm Res; 2006 May; 23(5):920-30. PubMed ID: 16715382 [TBL] [Abstract][Full Text] [Related]
10. Encapsulation of poorly soluble drugs in polymer-drug conjugates: effect of dual-drug nanoformulations on cancer therapy. Senanayake TH; Lu Y; Bohling A; Raja S; Band H; Vinogradov SV Pharm Res; 2014 Jun; 31(6):1605-15. PubMed ID: 24452808 [TBL] [Abstract][Full Text] [Related]
11. A novel cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to gemcitabine. Yang MY; Lee YB; Ahn CH; Kaye J; Fine T; Kashi R; Ohne O; Smid K; Peters GJ; Kim DJ Anticancer Res; 2014 Dec; 34(12):6951-9. PubMed ID: 25503121 [TBL] [Abstract][Full Text] [Related]
12. Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy. Zhang C; Pan D; Li J; Hu J; Bains A; Guys N; Zhu H; Li X; Luo K; Gong Q; Gu Z Acta Biomater; 2017 Jun; 55():153-162. PubMed ID: 28259838 [TBL] [Abstract][Full Text] [Related]
13. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents. Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933 [TBL] [Abstract][Full Text] [Related]
14. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway. Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057 [TBL] [Abstract][Full Text] [Related]
15. Self-assembled drug delivery systems. Part 8: In vitro/in vivo studies of the nanoassemblies of cholesteryl-phosphonyl gemcitabine. Li M; Qi S; Jin Y; Dong J Int J Pharm; 2015 Jan; 478(1):124-130. PubMed ID: 25448574 [TBL] [Abstract][Full Text] [Related]
16. Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer. Loc WS; Linton SS; Wilczynski ZR; Matters GL; McGovern CO; Abraham T; Fox T; Gigliotti CM; Tang X; Tabakovic A; Martin JA; Clawson GA; Smith JP; Butler PJ; Kester M; Adair JH Nanomedicine; 2017 Oct; 13(7):2313-2324. PubMed ID: 28673852 [TBL] [Abstract][Full Text] [Related]
17. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation. Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559 [TBL] [Abstract][Full Text] [Related]
18. Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs. Vinogradov SV; Zeman AD; Batrakova EV; Kabanov AV J Control Release; 2005 Sep; 107(1):143-57. PubMed ID: 16039001 [TBL] [Abstract][Full Text] [Related]
19. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor. Reddy LH; Renoir JM; Marsaud V; Lepetre-Mouelhi S; Desmaële D; Couvreur P Mol Pharm; 2009; 6(5):1526-35. PubMed ID: 19634915 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and ex-vivo release studies of colon-specific polyphosphazene-anticancer drug conjugates. Sharma R; Rawal RK; Malhotra M; Sharma AK; Bhardwaj TR Bioorg Med Chem; 2014 Feb; 22(3):1104-14. PubMed ID: 24405812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]